ライフサイエンスコーパス: respiratory syncytial virus

1 nterovirus and 30.7% influenza/parainfluenza/respiratory syncytial viruses).

2 diseases such as tuberculosis, influenza and respiratory syncytial virus.

3 ed robust neutralizing responses against the respiratory syncytial virus.

4 embling nanoparticle bearing an antigen from respiratory syncytial virus.

5 human metapneumovirus, influenza B virus and respiratory syncytial virus.

6 so includes rabies virus, measles virus, and respiratory syncytial virus.

7 account for 80% of the phosphoprotein of the respiratory syncytial virus.

8 monary function, and enhances lung injury by respiratory syncytial virus.

9 easonality of sCoVs with influenza virus and respiratory syncytial virus.

10 of respiratory viruses such as influenza and respiratory syncytial viruses.

11 nd was strongest for influenza/parainfluenza/respiratory syncytial viruses.

12 (influenza virus -0.2 months [-0.6 to 0.1]; respiratory syncytial virus 0.1 months [-0.2 to 0.4]).

13 pneumonia deaths (n = 32) were attributed to respiratory syncytial virus (21.9%), Pneumocystis jirove

14 f epidemics was similar across all sites for respiratory syncytial virus (4.6 months [4.3 to 4.8]), a

15 %), influenza virus (12%), coronavirus (9%), respiratory syncytial virus (6%), and metapneumovirus (6

16 246 sites for influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza

17 rainfluenza virus 4, rhinovirus/enterovirus, respiratory syncytial virus A and B, Bordetella pertussi

18 A study of respiratory syncytial virus-A (RSV A) genotype ON1 genet

19 l therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory trac

20 Unexpectedly, infection with respiratory syncytial virus alters Rab11A motion in a ma

21 espiratory syndrome coronavirus, Zika virus, respiratory syncytial virus and cytomegalovirus replicat

22 Previous respiratory syncytial virus and dengue virus vaccine stu

23 s to individual viruses including influenza, respiratory syncytial virus and dengue, but the generali

24 fic for clinically-relevant Ags derived from respiratory syncytial virus and HIV-1 also exhibited an

25 eutralizing monoclonal antibodies.IMPORTANCE Respiratory syncytial virus and human metapneumovirus ar

26 and all child mortality settings, similar to respiratory syncytial virus and influenza virus.

27 enomes (DVGs) in human infections, including respiratory syncytial virus and influenza, and growing e

28 sociated with higher levels of antibodies to respiratory syncytial virus and measles virus, compared

29 ifically in our step-down level 2 unit, with respiratory syncytial virus and parainfluenza virus bein

30 immunization appears to be within reach for respiratory syncytial virus and promising for influenza

31 1 effectively restricts replication of human respiratory syncytial virus and rhinoviruses.

32 a natural rodent pathogen that is related to respiratory syncytial virus and that generates local inf

33 ributing pathogens (influenza A/H1, A/H3, B, respiratory syncytial virus, and human parainfluenza vir

34 Respiratory syncytial virus antigens were detected in ci

35 Respiratory syncytial virus-associated acute respiratory

36 sed, uninfected infants have higher risks of respiratory syncytial virus-associated hospitalization t

37 Respiratory syncytial virus-bronchiolitis is a major ind

38 bronchial lymph node transcriptome to Bovine Respiratory Syncytial Virus (BRSV) in a controlled viral

39 rhea virus 1 and 2 (BVDV1 and BVDV2), bovine respiratory syncytial virus (BRSV), and bovine herpesvir

40 In this manuscript, we show that bovine respiratory syncytial virus (bRSV), which infects cattle

41 nfluenza virus epidemics occurred later than respiratory syncytial virus (by 0.3 months [95% CI -0.3

42 ramyxo-/pneumoviruses (e.g. Sendai virus and respiratory syncytial virus) by interfering with the vir

43 irus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in ch

44 In mice infected with respiratory syncytial virus, co-exposure to pollen cause

45 Respiratory syncytial virus-confirmed rates were highest

46 ropean Union Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU

47 n the history of developing vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and

48 Severe respiratory syncytial virus disease can be prevented by

49 ated with reduced prevalence and severity of respiratory syncytial virus disease in the first few wee

50 Small molecule inhibits respiratory syncytial virus entry and infection by block

51 the local onset month of influenza virus and respiratory syncytial virus epidemics.

52 The prospective Canadian Respiratory Syncytial Virus Evaluation Study of Palivizu

53 The respiratory syncytial virus fusion (F) glycoprotein trim

54 soybean agglutinin to selectively label the respiratory syncytial virus G protein in living cells wi

55 The human respiratory syncytial virus G protein plays an important

56 ch, we discovered that plasma membrane-bound respiratory syncytial virus G rapidly recycles from the

57 Unlike influenza virus, respiratory syncytial virus had clear seasonal epidemics

58 n understanding the human immune response to respiratory syncytial virus has paved the way for new va

59 Human respiratory syncytial virus (hRSV) is responsible for se

60 A molecular epidemiological study of human respiratory syncytial virus (HRSV) was conducted to exam

61 ajor difference with pre-fusion F from human respiratory syncytial virus (hRSV), and collectively our

62 uses that include rabies virus (RABV), human respiratory syncytial virus (HRSV), and Ebola virus (EBO

63 ent model to study the closely related human respiratory syncytial virus (hRSV).

64 thogenic viruses, including influenza virus, respiratory syncytial virus, human immunodeficiency viru

65 of influenza virus in temperate regions and respiratory syncytial virus in both temperate and tropic

66 The Influenza and Respiratory Syncytial Virus in Infants (IRIS) study was

67 cytial virus infection and resembled classic respiratory syncytial virus-induced bronchiolitis; and p

68 The at-home death rate due to respiratory syncytial virus infection among infants was

69 (49%), which has the largest probability of respiratory syncytial virus infection and resembled clas

70 Here we report that during Sendai and respiratory syncytial virus infections DVGs selectively

71 ategies to prevent group B streptococcus and respiratory syncytial virus infections, among others.

72 experimentally challenged with either bovine respiratory syncytial virus, infectious bovine rhinotrac

73 G protein in living cells without disrupting respiratory syncytial virus infectivity or filament form

74 Respiratory syncytial virus is a major cause of acute lo

75 resence of maternal IgG antibody specific to respiratory syncytial virus is associated with reduced p

76 Respiratory syncytial virus is pervasive across multiple

77 ldhood infection with parainfluenza virus or respiratory syncytial virus is strongly associated with

78 Respiratory syncytial virus is the leading cause of lowe

79 thing problems/eczema during infancy and non-respiratory syncytial virus (mostly rhinovirus) infectio

80 ere not detected by routine clinical workup (respiratory syncytial virus [n = 3], human metapneumovir

81 cluding the human pathogens rabies, measles, respiratory syncytial virus, Nipah, and Ebola, possess a

82 (odds ratio = 3.3; 95% CI, 1.5-7.1), but not respiratory syncytial virus (odds ratio = 1.0; 95% CI, 0

83 lobal epidemic months of influenza virus and respiratory syncytial virus on a 5 degrees by 5 degrees

84 to Feb 3, 2015, using the key terms "RSV", "respiratory syncytial virus", or "respiratory syncytial

85 asopharyngeal swab testing for influenza and respiratory syncytial virus over 4 days in March 2020.

86 month-by-month activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and me

87 Influenza virus, respiratory syncytial virus, parainfluenza virus, and me

88 data of human infection of influenza virus, respiratory syncytial virus, parainfluenza virus, or met

89 A respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coro

90 ynamic formation of filamentous and branched respiratory syncytial virus particles, and assembly with

91 for health services planning, the timing of respiratory syncytial virus passive prophylaxis, and the

92 unisation initiatives-group B streptococcus, respiratory syncytial virus, pertussis, and influenza.

93 ydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections

94 s for nonatopic asthma were the first severe respiratory syncytial virus/rhinovirus-negative wheezing

95 erovirus (4.5%), influenza A virus (3%), and respiratory syncytial virus (RSV) (2%).

96 (FluA) virus, influenza B (FluB) virus, and respiratory syncytial virus (RSV) (FFABR assay).

97 etection of either influenza virus (n = 29), respiratory syncytial virus (RSV) (n = 1), influenza vir

98 o determine the association of influenza and respiratory syncytial virus (RSV) activity with risk of

99 Respiratory syncytial virus (RSV) affects most infants e

100 acellular environments and here we show that respiratory syncytial virus (RSV) and herpes simplex vir

101 We aim to characterize the burden of respiratory syncytial virus (RSV) and human metapneumovi

102 Respiratory syncytial virus (RSV) and human metapneumovi

103 ses, human parainfluenza viruses 1-3 (HPIV), respiratory syncytial virus (RSV) and human metapneumovi

104 Respiratory syncytial virus (RSV) and human metapneumovi

105 The pathogenesis of respiratory syncytial virus (RSV) and influenza A virus

106 To follow eosinophil-virus interaction, respiratory syncytial virus (RSV) and influenza virus we

107 Other viral infections, such as respiratory syncytial virus (RSV) and rhinovirus, also s

108 circulating in the United States of America: respiratory syncytial virus (RSV) and seasonal influenza

109 Transplacental respiratory syncytial virus (RSV) antibody transfer has

110 Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, b

111 Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in development and

112 Here we show that RNAs of human respiratory syncytial virus (RSV) are modified by m(6)A

113 Influenza A and B viruses and respiratory syncytial virus (RSV) are three common virus

114 This study identified a genotype of respiratory syncytial virus (RSV) associated with increa

115 Rationale: Respiratory syncytial virus (RSV) bronchiolitis causes s

116 Infant respiratory syncytial virus (RSV) bronchiolitis in the f

117 This study evaluates the long-term respiratory syncytial virus (RSV) burden among preterm a

118 Few studies describe the respiratory syncytial virus (RSV) burden in African popu

119 ient spread and apical release were seen for respiratory syncytial virus (RSV) but not human metapneu

120 o were subsequently tested for influenza and respiratory syncytial virus (RSV) by a polymerase chain

121 s of cases due to Legionella, influenza, and respiratory syncytial virus (RSV) by age group.

122 Most individuals are infected with respiratory syncytial virus (RSV) by age two, but infect

123 The safety and immunogenicity of live respiratory syncytial virus (RSV) candidate vaccine, LID

124 Human parainfluenza virus 3 (HPIV3) and respiratory syncytial virus (RSV) cause lower respirator

125 rotection against RSV reinfection.IMPORTANCE Respiratory syncytial virus (RSV) causes disease early i

126 Respiratory syncytial virus (RSV) causes exacerbations o

127 Human respiratory syncytial virus (RSV) causes severe morbidit

128 ion against infection and disease.IMPORTANCE Respiratory syncytial virus (RSV) causes severe respirat

129 Respiratory syncytial virus (RSV) causes significant mor

130 Rationale: Respiratory syncytial virus (RSV) causes significant mor

131 Respiratory syncytial virus (RSV) causes substantial mor

132 association between the age at first severe respiratory syncytial virus (RSV) disease and subsequent

133 Infants with less severe respiratory syncytial virus (RSV) disease had higher vir

134 Despite the severity of respiratory syncytial virus (RSV) disease in older adult

135 n whether viral load affects the severity of respiratory syncytial virus (RSV) disease in outpatient

136 Respiratory syncytial virus (RSV) disease is a major cau

137 ar-old) are at most risk of life threatening respiratory syncytial virus (RSV) disease.

138 Higher RRs at 1-11 months suggested respiratory syncytial virus (RSV) etiology.

139 The respiratory syncytial virus (RSV) F glycoprotein is a cl

140 nd 25P13, both of which cross-react with the respiratory syncytial virus (RSV) F protein.

141 Presatovir is an oral respiratory syncytial virus (RSV) fusion inhibitor targe

142 Inhibitors of the respiratory syncytial virus (RSV) fusion protein block e

143 method, we recovered 13 (76%) complete human respiratory syncytial virus (RSV) genomes from 17 clinic

144 We aimed to study respiratory syncytial virus (RSV) genotype distribution,

145 Data on how respiratory syncytial virus (RSV) genotypes influence di

146 Respiratory syncytial virus (RSV) has eluded active vacc

147 In the United States, the seasonality of respiratory syncytial virus (RSV) has traditionally been

148 Despite the prevalence of respiratory syncytial virus (RSV) in adults hospitalized

149 asopharyngeal microbiota to the clearance of respiratory syncytial virus (RSV) in infants hospitalize

150 Despite the high disease burden of respiratory syncytial virus (RSV) in older adults, there

151 The significant burden of Respiratory Syncytial Virus (RSV) in pediatric and elder

152 However, both respiratory syncytial virus (RSV) infection and mutation

153 udies of the immune responses at the site of respiratory syncytial virus (RSV) infection are sparse d

154 Respiratory syncytial virus (RSV) infection causes signi

155 Early life respiratory syncytial virus (RSV) infection has been lin

156 Severe disease following respiratory syncytial virus (RSV) infection has been lin

157 infection with Heligmosomoides polygyrus on respiratory syncytial virus (RSV) infection in a mouse m

158 We aimed to explore the association between respiratory syncytial virus (RSV) infection in early lif

159 Respiratory syncytial virus (RSV) infection in lung tran

160 Respiratory syncytial virus (RSV) infection in mouse and

161 rge cohort of older adults hospitalized with respiratory syncytial virus (RSV) infection in the Unite

162 Respiratory syncytial virus (RSV) infection induces asth

163 Respiratory syncytial virus (RSV) infection is a leading

164 Severe respiratory syncytial virus (RSV) infection is a major c

165 Respiratory syncytial virus (RSV) infection is an import

166 Respiratory syncytial virus (RSV) infection is epidemiol

167 Respiratory syncytial virus (RSV) infection is the leadi

168 Respiratory syncytial virus (RSV) infection of children

169 Respiratory syncytial virus (RSV) infection of seronegat

170 Clinical manifestations of respiratory syncytial virus (RSV) infection vary widely

171 t approach to the protection of infants from respiratory syncytial virus (RSV) infection, a severe ac

172 ligand 4 (Dll4) was upregulated on APC after respiratory syncytial virus (RSV) infection, and its inh

173 nterventions are in clinical development for respiratory syncytial virus (RSV) infection, including s

174 anscriptomic response in children with acute respiratory syncytial virus (RSV) infection, symptomatic

175 Using a murine CB6F1/J hybrid model of respiratory syncytial virus (RSV) infection, we previous

176 N) and inflammatory cytokines in response to respiratory syncytial virus (RSV) infection.

177 (IFI44L), as potentially being important in respiratory syncytial virus (RSV) infection.

178 The use of oral ribavirin (RBV) for respiratory syncytial virus (RSV) infections is not well

179 Respiratory syncytial virus (RSV) infections remain a ma

180 rts have described the contribution of adult respiratory syncytial virus (RSV) infections to the use

181 E Respiratory viral infections, like IAV and respiratory syncytial virus (RSV) infections, impose gre

182 5), human parainfluenza virus 3 (HPIV3), and respiratory syncytial virus (RSV) infections.

183 flammatory responses of AM following IAV and respiratory syncytial virus (RSV) infections.

184 Respiratory syncytial virus (RSV) infects and causes dis

185 Respiratory syncytial virus (RSV) inflicts a significant

186 Respiratory syncytial virus (RSV) is a common cause of r

187 g candidate vaccine antigen.IMPORTANCE Human respiratory syncytial virus (RSV) is a global leading ca

188 Respiratory syncytial virus (RSV) is a globally prevalen

189 Pulmonary infection by the respiratory syncytial virus (RSV) is a large burden on h

190 Respiratory syncytial virus (RSV) is a leading cause of

191 Respiratory syncytial virus (RSV) is a leading cause of

192 Respiratory syncytial virus (RSV) is a leading cause of

193 Respiratory syncytial virus (RSV) is a leading cause of

194 Respiratory syncytial virus (RSV) is a leading cause of

195 Respiratory syncytial virus (RSV) is a leading cause of

196 Respiratory syncytial virus (RSV) is a major cause of ac

197 Respiratory syncytial virus (RSV) is a major cause of ch

198 Respiratory syncytial virus (RSV) is a major cause of ho

199 Respiratory syncytial virus (RSV) is a major cause of lo

200 Respiratory syncytial virus (RSV) is a major cause of pe

201 Respiratory syncytial virus (RSV) is a major cause of pn

202 Respiratory syncytial virus (RSV) is a major cause of se

203 Human respiratory syncytial virus (RSV) is a major pediatric r

204 Respiratory syncytial virus (RSV) is a nonsegmented nega

205 Respiratory syncytial virus (RSV) is a seasonal virus th

206 Respiratory syncytial virus (RSV) is a significant cause

207 r neutralizing antibodies in dams.IMPORTANCE Respiratory syncytial virus (RSV) is a significant human

208 Respiratory syncytial virus (RSV) is a top cause of seve

209 Respiratory syncytial virus (RSV) is a worldwide public

210 Respiratory syncytial virus (RSV) is among the most impo

211 Respiratory syncytial virus (RSV) is an exceptional muco

212 Respiratory syncytial virus (RSV) is an important cause

213 Respiratory syncytial virus (RSV) is an important cause

214 Respiratory syncytial virus (RSV) is an important cause

215 e nonsegmented negative-strand RNA genome of respiratory syncytial virus (RSV) is encapsidated by the

216 Respiratory syncytial virus (RSV) is no exception, as it

217 The Human respiratory syncytial virus (RSV) is one of the most imp

218 Respiratory syncytial virus (RSV) is recognised as a lea

219 Although respiratory syncytial virus (RSV) is responsible for mor

220 MPORTANCE Despite decades of research, human respiratory syncytial virus (RSV) is still a major healt

221 Respiratory syncytial virus (RSV) is the dominant cause

222 Respiratory syncytial virus (RSV) is the leading cause o

223 Respiratory syncytial virus (RSV) is the leading cause o

224 Human respiratory syncytial virus (RSV) is the leading cause o

225 Human respiratory syncytial virus (RSV) is the leading cause o

226 Respiratory syncytial virus (RSV) is the leading cause o

227 Respiratory syncytial virus (RSV) is the leading cause o

228 Respiratory syncytial virus (RSV) is the leading global

229 Human respiratory syncytial virus (RSV) is the leading viral c

230 Respiratory syncytial virus (RSV) is the leading viral c

231 Respiratory syncytial virus (RSV) is the leading viral p

232 Respiratory syncytial virus (RSV) is the most common cau

233 Respiratory syncytial virus (RSV) is the most common cau

234 Respiratory syncytial virus (RSV) is the most common cau

235 Respiratory syncytial virus (RSV) is the most common vir

236 Respiratory syncytial virus (RSV) is the most important

237 Human respiratory syncytial virus (RSV) is the most prevalent

238 Respiratory syncytial virus (RSV) is the primary cause o

239 A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and pa

240 Antiviral drug development against respiratory syncytial virus (RSV) is urgently needed due

241 ns.IMPORTANCE Strain-specific differences in respiratory syncytial virus (RSV) isolates are associate

242 The association between respiratory syncytial virus (RSV) loads and clinical out

243 Respiratory syncytial virus (RSV) lower respiratory trac

244 In patients with controlled HIV or cleared respiratory syncytial virus (RSV) or influenza virus inf

245 mplates for transcription and replication by respiratory syncytial virus (RSV) polymerase are helical

246 Respiratory syncytial virus (RSV) remains a major human

247 associated with enhanced rhinovirus (RV) and respiratory syncytial virus (RSV) replication.

248 Respiratory syncytial virus (RSV) represents a threat to

249 The respiratory syncytial virus (RSV) RNA polymerase, consti

250 ational age (wGA) infants aged <12 months at respiratory syncytial virus (RSV) season start.

251 The study was conducted during respiratory syncytial virus (RSV) seasons, before pneumo

252 We administered respiratory syncytial virus (RSV) to 58 volunteers, of w

253 open reading frames (ORFs) in the genome of respiratory syncytial virus (RSV) to codon pair optimiza

254 Respiratory syncytial virus (RSV) typically causes winte

255 candidate.IMPORTANCE A safe and efficacious respiratory syncytial virus (RSV) vaccine remains elusiv

256 progress has been made towards an effective respiratory syncytial virus (RSV) vaccine.

257 We have previously estimated that respiratory syncytial virus (RSV) was associated with 22

258 Here, various ORFs in the genome of respiratory syncytial virus (RSV) were codon pair optimi

259 Nearly all children are infected with respiratory syncytial virus (RSV) within the first 2 yea

260 s yet, there is no effective vaccine against respiratory syncytial virus (RSV), a ubiquitous pathogen

261 Here, we evaluate the climate drivers of respiratory syncytial virus (RSV), an important determin

262 administration are being developed for human respiratory syncytial virus (RSV), an important worldwid

263 ed rapid tests for influenza viruses, 32 for respiratory syncytial virus (RSV), and 13 for other resp

264 With the majority of bronchiolitis caused by respiratory syncytial virus (RSV), and several RSV vacci

265 missibility of respiratory viruses including respiratory syncytial virus (RSV), but there are few stu

266 tion in early childhood, including that from respiratory syncytial virus (RSV), has been previously a

267 pathogens, such as, but not limited to, HIV, respiratory syncytial virus (RSV), herpes simplex virus

268 R (RT-PCR) and serology for the diagnosis of respiratory syncytial virus (RSV), human metapneumovirus

269 ed infections caused by the same serotype of respiratory syncytial virus (RSV), in contrast to infect

270 mong the exposed (AFE) for 8 common viruses: respiratory syncytial virus (RSV), influenza virus (Flu)

271 rway epithelial cells are the main target of respiratory syncytial virus (RSV), it also infects immun

272 Paramyxoviridae and Pneumoviridae, including respiratory syncytial virus (RSV), mumps virus, and huma

273 , 457 of 605 (75.5%) infants with influenza, respiratory syncytial virus (RSV), or human metapneumovi

274 exposure significantly increased the risk of respiratory syncytial virus (RSV)-associated hospitaliza

275 Data describing influenza- or respiratory syncytial virus (RSV)-associated hospitalize

276 Of 2322 HIV-uninfected children with respiratory syncytial virus (RSV)-associated LRTI, 1330

277 onchiolitis (or first wheezing episode): (a) respiratory syncytial virus (RSV)-induced bronchiolitis,

278 a hallmark of severe disease in infants with respiratory syncytial virus (RSV)-induced lower respirat

279 Respiratory syncytial virus (RSV)-related acute lower re

280 netics, safety, and antiviral effects of the respiratory syncytial virus (RSV)-specific fusion inhibi

281 y tract infections caused by viruses such as respiratory syncytial virus (RSV).

282 there are no FDA-approved vaccines for human respiratory syncytial virus (RSV).

283 responses to RNA viral infections, including respiratory syncytial virus (RSV).

284 ratory tract infections including those from respiratory syncytial virus (RSV).

285 compared hospitalization rates for HMPV and respiratory syncytial virus (RSV).

286 human rhinovirus (HRV), influenza virus, and respiratory syncytial virus (RSV).

287 litis were enrolled (77% tested positive for respiratory syncytial virus [RSV]).

288 However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, an

289 , 30.2%-60.2%) of sCoV cases occurred during respiratory syncytial virus season.

290 Respiratory syncytial virus-seronegative children ages 6

291 Respiratory syncytial virus tests and detections were cl

292 modelled monthly AAP of influenza virus and respiratory syncytial virus using site-specific temperat

293 d the strategy of influenza virus and future respiratory syncytial virus vaccination.

294 those in humans given inactivated measles or respiratory syncytial virus vaccines.

295 formation and allowing for interrogations of respiratory syncytial virus virion assembly.

296 Respiratory syncytial virus was detected in community, E

297 Respiratory syncytial virus was detected more frequently

298 (34%), and parainfluenza virus type 3 (28%); respiratory syncytial virus was highly concordant (92%).

299 ions of antiviral activity against the human respiratory syncytial virus were carried out for selecte

300 Rhinovirus, common human coronaviruses, and respiratory syncytial virus were the most common.